— Weight Loss · Reference
Do Peptides Affect Fertility? What Is Known and What Is Not
This page separates the categories properly: a small amount of real human evidence, almost all of it about GLP-1 medications and body weight, and a much larger area where the honest statement is that no human fertility data exists.
— Treatments mentioned
For most peptides the honest answer is that fertility outcomes have not been studied, so nobody can tell you the effect either way. The exceptions are specific and worth knowing: GLP-1 medications carry guidance about discontinuing in advance of a planned pregnancy, weight loss can restore ovulation in people who were not ovulating regularly, and exogenous testosterone suppresses sperm production, which matters if peptides are being added to an existing TRT protocol. If conception is your near-term goal, say so before starting anything, because that single disclosure changes what a physician will prescribe and when.
This page separates the categories properly: a small amount of real human evidence, almost all of it about GLP-1 medications and body weight, and a much larger area where the honest statement is that no human fertility data exists.
— Do Peptides Affect Fertility? What Is Known and What Is Not
The short answer
| Your situation | What is known | What to do |
|---|---|---|
| Trying to conceive now | Fertility data is absent for most of this category | Tell your prescriber before starting or continuing anything |
| On a GLP-1 and planning pregnancy | Specific guidance exists about stopping in advance | Ask your physician about timing |
| On a GLP-1 and not trying to conceive | Weight loss can restore ovulation; fertility may rise unexpectedly | Have the contraception conversation at the start |
| On a GH-axis peptide and trying to conceive | Limited human data; growth signalling interacts with reproductive endocrinology | The low-risk path is to pause elective treatment. Ask your physician |
| Male, on testosterone therapy | Sperm production is suppressed by exogenous testosterone. This is well documented | A specific conversation before conceiving, see can you take peptides with testosterone |
| Already pregnant | Peptide therapy is not used. See can you take peptides while pregnant | Stop and contact your physician the same day |
State your intention to conceive at the intake stage rather than after a prescription is written. It changes the medication, the timing and the contraception discussion at once.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Why the data is missing
Fertility outcomes are difficult and expensive to study, and they are almost never an endpoint in the research that supports compounded peptide therapy. For the repair and growth-hormone-axis peptides, the evidence base overall is largely preclinical: animal and cell studies rather than large human trials. Fertility sits outside even that.
This is not a case of researchers looking and finding nothing concerning. It is a case of nobody having looked. Those are very different situations, and a provider who reports the second as the first is misleading you.
Fertility is almost never an endpoint
A fertility trial needs couples actively trying to conceive, a control group, and a primary outcome — live birth — that can take two years to accrue. Trials designed around tendon healing, visceral fat or sleep quality do not collect it, and regulators do not require them to. What the reproductive-toxicology system does require, for an approved drug, is animal reproduction studies, with mating, conception, estrus cycling and offspring development recorded. Those exist for the approved GLP-1 medications and are summarized below. They do not exist in the public literature for most compounded peptides.
Absence of evidence is not evidence of safety
A molecule with no reported fertility problem and a molecule with a fertility problem nobody measured look identical from the outside. The correct response is neither alarm nor reassurance, but the ordinary clinical answer: do not be on elective treatment during the window that matters unless a physician has weighed a specific reason to continue.
| Category | What is known about fertility | Honest summary |
|---|---|---|
| GLP-1 medications | Specific guidance exists about discontinuing before a planned pregnancy. Weight loss itself affects ovulation. Delayed gastric emptying raises questions about absorption of oral medications | The most is known here, and it still requires a physician conversation |
| Growth-hormone-axis peptides | Growth hormone and IGF-1 signalling interact with reproductive endocrinology, but human fertility outcome data in this use is absent | No usable data. Pausing is the cautious path |
| Kisspeptin | Kisspeptin is a regulator of GnRH release and is genuinely studied in reproductive endocrinology | Acting on the reproductive axis is not the same as being a fertility treatment. Prescriber territory |
| Repair peptides, BPC-157, TB-500, GHK-Cu, KPV | No fertility data | Unknown |
| Cognitive, sleep and intimacy peptides | No fertility data | Unknown |
— Do Peptides Affect Fertility? What Is Known and What Is Not
The reproductive axis, briefly
Reproduction in both sexes runs on a pulse generator in the hypothalamus that releases gonadotropin-releasing hormone in bursts. Those bursts drive the pituitary to release luteinizing hormone and follicle-stimulating hormone, which drive the ovary to mature a follicle and ovulate, or the testis to produce testosterone inside the testis and support sperm production. The pulse pattern matters as much as the amount: continuous stimulation shuts that system down, which is how GnRH-agonist medications are used clinically.
Kisspeptin neurons are the switch immediately above that pulse generator. The clearest evidence this is not a theory is genetic: loss-of-function changes in the kisspeptin receptor cause hypogonadotropic hypogonadism and failure to enter puberty, reported independently in the New England Journal of Medicine and in PNAS in 2003.
The same circuitry integrates energy availability. Chronic energy deficit suppresses the pulse generator, the mechanism behind hypothalamic amenorrhea. Excess adiposity and insulin resistance disturb the axis differently — raised androgens, altered pulse frequency, disrupted follicle selection — which is the clinical picture of polycystic ovary syndrome. This is why weight change is the one intervention here with a measured fertility effect, and why it can run in either direction.
— Do Peptides Affect Fertility? What Is Known and What Is Not
GLP-1 medications and the fertility questions people miss
Three separate things come up here, and they are often run together.
The pre-pregnancy guidance. There is specific guidance about discontinuing a GLP-1 in advance of a planned pregnancy. The timing depends on the medication and on your circumstances, and it is a question for your physician rather than a number to read off a page.
Fertility can increase. Weight loss can restore ovulation in people who were not ovulating regularly, including in the context of PCOS. Someone who had assumed conception was unlikely can find that assumption is no longer accurate during treatment. That is the practical reason the contraception conversation happens at the start rather than being treated as a formality.
Oral medication absorption. Because these medications slow gastric emptying, the guidance for the branded tirzepatide product addresses the absorption of oral contraceptives and advises a plan around starting and around dose increases. If you rely on an oral contraceptive, this is not a detail to skip: ask your physician specifically what they recommend for you and for how long.
— What the approved semaglutide label actually says
The FDA-approved label for the branded semaglutide product states, under Females and Males of Reproductive Potential, that patients using it for weight reduction or cardiovascular risk reduction should discontinue it at least two months before a planned pregnancy, because of the long half-life of semaglutide. The same label directs that it be discontinued when a pregnancy is recognized in those populations, and notes a pregnancy exposure registry that monitors outcomes in people exposed during pregnancy.
That is the source of the "two months" figure, and it applies to the molecule rather than a particular brand. The pharmacokinetics section explains the interval: an elimination half-life of approximately one week, with semaglutide present in the circulation for about five to seven weeks after the last dose. Two months is that washout plus a margin.
Tirzepatide is cleared faster — its approved label gives an elimination half-life of approximately five days in people with overweight or obesity — but a shorter half-life is not permission to improvise. That labeling carries no pre-pregnancy discontinuation interval, which makes the interval for tirzepatide a clinical judgment rather than a published number.
— Tirzepatide, oral contraceptives and the four-week rule
This is the most frequently missed item on the page. The approved label for the branded tirzepatide product states that its use may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying, that the delay is largest after the first dose and diminishes over time, and that patients using oral hormonal contraceptives should switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase. The same section notes that hormonal contraceptives not taken by mouth are not expected to be affected.
The pharmacology behind it: with a single dose of tirzepatide, peak concentrations of the components of a combined oral contraceptive were substantially reduced and the time to peak delayed by several hours, while total exposure fell far less. The pill is absorbed later and less sharply while the stomach empties slowly.
Semaglutide differs here. The drug interactions section of its approved label reports no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel when given alongside semaglutide. That is a real difference between the two molecules.
— What the animal reproduction studies reported
Both approved labels describe reproductive-toxicology studies in animals, and both state the medication may cause fetal harm and should be discontinued when pregnancy is recognized in the weight-reduction population.
The fertility-specific findings are narrower than people assume. In the combined fertility and embryofetal development study in rats described in the approved semaglutide label, no effects were observed on male fertility; in females, estrus-cycle length increased at all dose levels with a small reduction in corpora lutea, which the label calls likely an adaptive response secondary to the drug's effect on food consumption and body weight. The approved tirzepatide label reports the parallel study: no effects on sperm morphology, mating, fertility or conception, and in female rats prolonged diestrus and fewer corpora lutea at all dose levels, again attributed to food consumption and body weight.
The animal cycle findings track energy intake rather than a direct effect on the ovary, and neither program reported an effect on male fertility parameters. Neither is a human fertility study.
— The compounded preparation does not come with that label
Pepti dispenses compounded semaglutide and compounded tirzepatide, prescribed by a physician licensed in your state and prepared by a state-licensed US pharmacy. A compounded preparation is not an FDA-approved finished drug product and carries no FDA-approved labeling. The approved labels above are the reference source physicians use for the molecule, and their pregnancy and contraception guidance is exactly the information that does not reach you automatically when a medication is compounded.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Weight loss, ovulation and PCOS
This is the one place on the page with human randomized evidence, and it deserves stating at full strength rather than hedging into uselessness.
— What PCOS does to ovulation
In polycystic ovary syndrome, raised androgens, insulin resistance and altered gonadotropin pulse frequency combine to prevent a follicle being selected and released reliably. Cycles become long or absent, and conception becomes unpredictable rather than impossible. Because insulin resistance and adiposity are part of that mechanism rather than an incidental finding, changing body weight changes the mechanism.
— The preconception weight-loss trial
A randomized controlled study in the Journal of Clinical Endocrinology and Metabolism in 2015 assigned 149 women with infertility due to PCOS and a BMI between 27 and 42 to sixteen weeks of continuous oral contraceptive pills, a lifestyle weight-loss program, or both, before all groups underwent standardized ovulation induction. Cumulative ovulation rates were 46 percent in the oral contraceptive group, 60 percent with lifestyle and 67 percent combined — a statistically significant difference favoring weight loss. Live birth rates were numerically higher in the weight-loss arms, 26 and 24 percent versus 12 percent, but that difference did not reach statistical significance.
That is the shape of the real evidence: weight loss before conception measurably improved ovulation, with a live-birth signal the study could not confirm.
— What a randomized trial of semaglutide in PCOS reported
A randomized, controlled, open-label trial in Reproductive Biology and Endocrinology in 2025 assigned 100 women with overweight or obesity and PCOS to sixteen weeks of metformin alone or metformin plus once-weekly semaglutide, after which all continued on metformin alone and pregnancy outcomes were followed to week 40. The combination group lost more weight, showed greater reductions in testosterone and inflammatory markers, had higher rates of menstrual cycle recovery, and had a higher natural pregnancy rate over the follow-up window, 35 percent versus 15 percent. Eighty of the 100 enrolled completed the study.
A single, modestly sized, open-label trial from one center is not grounds to call semaglutide a fertility treatment. It is direct human evidence that treatment aimed at weight and metabolic parameters can be followed by more conception, not less.
— Which is why contraception belongs in the first conversation
Put the two trials together. Someone who has not been ovulating reliably, who organized contraception around the assumption that conception was unlikely, and who then loses substantial weight on semaglutide or tirzepatide, may become more likely to conceive during exactly the window the approved labeling advises against pregnancy. That is why a careful prescriber raises contraception at the first visit.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Kisspeptin, the one molecule here with a reproductive literature
Kisspeptin is the exception, and the distinction between "acts on the reproductive axis" and "is a fertility treatment" has to be held carefully.
— What the human studies report
Kisspeptin-54 was reported to stimulate the hypothalamic–pituitary–gonadal axis in men in the Journal of Clinical Endocrinology and Metabolism in 2005, and the same group reported in 2007 that gonadotropin release in women was most marked during the preovulatory phase. Kisspeptin-10 was reported to increase LH pulse frequency in men in the same journal in 2011. In women with hypothalamic amenorrhea it acutely stimulated gonadotropin secretion, but the 2009 report also documented tachyphylaxis with chronic administration.
— Kisspeptin in assisted reproduction
The most fertility-specific work is its use as a trigger for egg maturation: kisspeptin-54 was reported to trigger oocyte maturation in women undergoing in vitro fertilization in the Journal of Clinical Investigation in 2014, followed by work in women at high risk of ovarian hyperstimulation syndrome in 2015 and a phase 2 randomized trial of a second dose in Human Reproduction in 2017. All of it was conducted inside monitored IVF cycles by reproductive endocrinologists.
— Why none of that makes it a fertility treatment here
Kisspeptin is not prescribed by Pepti as a fertility treatment and is not a substitute for fertility care. That literature is a reason to treat it with more care than the rest of the catalog when conception is the goal, not less. Anyone actively trying, or in an IVF cycle, should raise kisspeptin with the physician managing that care first. Background is in what is kisspeptin.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Growth-hormone-axis peptides
Sermorelin, ipamorelin, CJC-1295 / ipamorelin and tesamorelin act on the growth hormone axis rather than the reproductive axis. Sermorelin and tesamorelin have real human trial data, in growth hormone deficiency and in HIV-associated visceral fat accumulation respectively; neither literature includes fertility endpoints.
Where the reproductive question comes from
Growth hormone and IGF-1 are not inert in the ovary or testis. IGF-1 acts as a co-factor in follicular development, the rationale behind a long-running question in assisted reproduction: whether adjuvant growth hormone improves outcomes in women who respond poorly to ovarian stimulation. A Cochrane review published in 2021 pooled 16 randomized trials in 1,352 women and concluded that adjuvant growth hormone slightly increases pregnancy rates and mean oocytes retrieved in poor responders, with the effect on live birth rates very uncertain and the certainty of the evidence rated low to very low.
What that does and does not tell you about sermorelin
Almost nothing, and the reason matters. Those trials used recombinant growth hormone, at fertility-clinic doses, inside a monitored stimulation cycle. Sermorelin, ipamorelin and tesamorelin are secretagogues — they ask the pituitary to release its own growth hormone within its own feedback constraints, a different exposure. No randomized human trial has measured fertility outcomes for any GH-axis secretagogue here. Growth signalling and reproductive endocrinology interact; that is a reason for caution rather than a measured effect in either direction.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Repair, cognitive, sleep and intimacy peptides
The repair peptides
BPC-157, TB-500, GHK-Cu and KPV have no human fertility data at all. There are no randomized controlled trials of BPC-157 in humans for any indication, and the mechanistic literature — angiogenesis, cell migration, gut lining protection — is animal and cell work. Nothing in it describes an effect on gametes, on the hypothalamic–pituitary–gonadal axis or on early pregnancy, because nothing in it looked. The same holds for TB-500, GHK-Cu, semax, selank and DSIP. "Unknown" is the correct word.
Desire is not fertility
PT-141 and oxytocin both have human randomized trial evidence, and it is evidence about sexual desire and arousal, not conception. Neither is a fertility treatment, neither has fertility outcome data in this use, and oxytocin in particular has obstetric pharmacology that makes a physician conversation non-optional if pregnancy is possible.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Men, and the part that gets skipped
Fertility questions come up less often from men and they matter equally.
The clearest issue is not the peptides. Exogenous testosterone suppresses sperm production, sometimes substantially and not always quickly reversibly. If you are on testosterone replacement and conception is a goal, that is the conversation to have first, and adding a GH-axis peptide does not change it. Do not assume any peptide protects fertility on TRT, because none of the ones described here is a fertility treatment.
— Why testosterone does this
Exogenous testosterone suppresses LH and FSH, and with them the intratesticular testosterone concentration, which is far higher than the level in blood and is a prerequisite for normal sperm production. A review in Translational Andrology and Urology in 2013 set this out and described the strategies andrologists use to preserve testicular function in men of reproductive age. A blood testosterone level that looks adequate says little about the concentration inside the testis.
— How reversible it is, in numbers
The best data comes from hormonal male contraception trials, where suppression was the goal and recovery was tracked systematically. An integrated analysis of 30 studies in 1,549 men, published in the Lancet in 2006, reported a median 3.4 months for sperm concentration to return to 20 million per mL, with a typical probability of reaching that threshold of 67 percent within 6 months, 90 percent within 12 months and 100 percent within 24 months. Those were healthy volunteers on defined protocols, so the timeline is an orientation rather than a promise.
— The ordinary causes, which are more common
Beyond that, the picture in men is the ordinary one: weight, sleep, alcohol, heat exposure, medications and untreated conditions all affect semen parameters, and these are found by assessment rather than assumed. A meta-analysis in Andrologia in 2021, restricted to men from the general population rather than infertility clinics, reported that obesity was associated with reduced semen volume, total sperm number, forward progression and viability, without a significant difference in sperm concentration or morphology. What to look at first is in peptides for men over 40.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Where these stand with the FDA right now
Compounded medications are not FDA approved
Every preparation discussed here is prepared by a licensed pharmacy pursuant to a prescription rather than approved by the FDA as a finished drug product. None is approved for a fertility indication and none is prescribed here as one. The branded reference products are approved, which is why their labeling exists and is the correct source for the guidance above.
What the advisory committee actually reviewed in 2026
The FDA's Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to consider several peptides for inclusion on the 503A Bulks List. The Federal Register notice lists the substances and the single use the FDA evaluated for each: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide (DSIP) for opioid withdrawal, chronic insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia.
Read that list with fertility in mind: not one substance was evaluated for a reproductive indication.
— Do Peptides Affect Fertility? What Is Known and What Is Not
What a physician rules out first
A fertility conversation that starts and ends with "should I stop my peptide" has usually skipped the more likely answers. Before a peptide is near the top of the list, a physician is thinking about thyroid function, prolactin, insulin resistance, cycle regularity and its history, age, previous pregnancies, pelvic and structural causes, medications already in the picture, alcohol, nicotine, sleep, and for men a semen analysis — the highest-yield test in the workup and frequently not done until late.
A peptide prescribed for recovery, sleep or body composition is rarely the explanation for difficulty conceiving, and treating it as the explanation delays finding the one that is.
— Do Peptides Affect Fertility? What Is Known and What Is Not
Monitoring and bloodwork
Bloodwork does not substitute for a physician's assessment. The markers that affect fertility in their own right are ordinary: thyroid function, prolactin, metabolic and glycemic markers, and in men a morning total testosterone with LH and FSH, which together distinguish suppression from a primary testicular problem. At-home blood testing covers hormone, metabolic and thyroid markers without a lab visit, and do you need bloodwork before peptides covers what is worth testing first.
What bloodwork cannot tell you is whether a peptide with no human fertility data is affecting your fertility, because no marker would show it.
— Do Peptides Affect Fertility? What Is Known and What Is Not
What to ask your physician
| Question | Why it matters |
|---|---|
| Should I stop this before trying to conceive, and how far in advance? | The answer differs by medication and by your history |
| Does anything I take affect my contraception? | Particularly relevant with oral contraceptives on a GLP-1 |
| Could treatment make me more fertile than I expect? | Weight loss can restore ovulation |
| What should I do if I become pregnant unexpectedly? | Know the plan before you need it |
| Which of these can I stay on while trying? | Ask for the reasoning, not just a yes or no |
| What bloodwork would be useful first? | Thyroid and metabolic markers affect fertility in their own right, see do you need bloodwork before peptides |
| If I am on TRT, what happens to sperm production? | This is the best-documented effect in the whole discussion |
A physician who answers these with confident reassurance rather than with the limits of what is known is not giving you a better answer, only a more comfortable one.
— Do Peptides Affect Fertility? What Is Known and What Is Not
If you conceive unexpectedly while on treatment
Contact your physician the same day. For the GLP-1 medications the approved labeling for the weight-reduction population is explicit that they are discontinued when a pregnancy is recognized, and both approved products have pregnancy exposure registries your physician can tell you about. The rest is in can you take peptides while pregnant.
— Do Peptides Affect Fertility? What Is Known and What Is Not
What the evidence shows, honestly
For most of this category, nobody can quote you fertility outcome data because it has not been collected. That sentence is the core of the page and it should not be softened.
Where evidence does exist it is indirect. Weight and metabolic health affect fertility in well-documented ways, which cuts both directions: obesity and insulin resistance are associated with reduced fertility, and substantial weight loss can restore ovulation. That says something about the effects of successful treatment on fertility. It says nothing about the direct effects of the molecule on gametes, on early pregnancy, or on anything else that has not been measured.
Kisspeptin is the one molecule in the catalogue with a genuine reproductive-endocrinology research literature behind it, because kisspeptin signalling regulates GnRH release and is being investigated in that context. That is a reason to take it seriously as an agent acting on the reproductive axis, not a basis for using it as a fertility treatment. More on it is in what is kisspeptin.
None of these compounded preparations is FDA approved, and none is prescribed here as a fertility treatment. If conception is the near-term goal, the low-risk path is to pause elective treatment and ask your physician what is reasonable to continue, which is the conclusion the absence of data actually supports.
— References
What this is based on.
References
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules (2014) · PMID 25415472
- Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment of rat and stable gastric pentadecapeptide BPC 157 · Journal of Orthopaedic Research (2006) · PMID 16583442
- Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design (2011) · PMID 21548867
- Cerovecki T, Bojanic I, Brcic L, Radic B, et al.. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res (2010) · PMID 20225319
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al.. Stable gastric pentadecapeptide BPC 157-NO-system relation · Curr Pharm Des (2014) · PMID 23755725
- Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H · Drug Test Anal (2017) · PMID 28035768
- Thomas A, Görgens C, Guddat S et al.. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry · J Sep Sci (2016) · PMID 26578461
- Farrar JT, Young JP Jr, LaMoreaux L, Werth JL et al.. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale · Pain (2001) · PMID 11690728
- Meyer JD, Ho B, Manning MC. Effects of conformation on the chemical stability of pharmaceutically relevant polypeptides · Pharm Biotechnol (2002) · PMID 11987755
- Xu C, Sun L, Ren F, Huang P, et al.. Preclinical Safety Evaluation of Body Protective Compound-157, a Potential Drug for Treating Various Wounds · Regul Toxicol Pharmacol (2020) · PMID 32334036
- He L, Feng D, Guo H, et al.. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs · Front Pharmacol (2022) · PMID 36588717
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain · Altern Ther Health Med (2021) · PMID 34324435
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
— Common questions
Do Peptides Affect Fertility? What Is Known and What Is Not, answered.
There is no evidence that they do, and for most of this category there is no fertility data at all, so an honest answer is that the effect is unknown rather than that it is nil. If conception is a near-term goal, discuss pausing with your physician. The one well-documented effect here is not a peptide at all — it is exogenous testosterone suppressing sperm production.
There is no fertility data on BPC-157 in humans, and the overall evidence base for it is largely preclinical. The cautious approach while actively trying is not to be on elective treatment, and that decision belongs to your physician. BPC-157 was reviewed by the FDA's compounding advisory committee in July 2026 for ulcerative colitis, the only use the agency evaluated.
Indirectly and in both directions. Weight loss can restore ovulation in people who were not ovulating regularly, and there is specific guidance about discontinuing in advance of a planned pregnancy. Ask your prescriber about timing for your situation. The approved label for the branded semaglutide product advises discontinuing at least two months before a planned pregnancy because of the long half-life of the molecule.
It is possible, which is why the contraception conversation happens at the start. People who had assumed conception was unlikely sometimes find that is no longer the case during treatment. A randomized trial in Reproductive Biology and Endocrinology in 2025 reported a higher natural pregnancy rate in women with PCOS on semaglutide plus metformin than on metformin alone.
Guidance for the branded product addresses oral contraceptive absorption around starting and around dose increases, because gastric emptying is slowed. Ask your physician what they recommend for you specifically and for how long. The approved label advises switching to a non-oral method or adding a barrier method for four weeks after starting tirzepatide and four weeks after each dose increase, and notes non-oral hormonal methods are not expected to be affected.
Human fertility outcome data in this use is absent. Growth hormone and IGF-1 signalling do interact with reproductive endocrinology, which is a reason for caution rather than a measured effect. Ask your physician. The adjuvant growth hormone trials in IVF used recombinant growth hormone, not a secretagogue like sermorelin, and a 2021 Cochrane review rated that evidence low to very low certainty.
That depends entirely on what changed and why, and for most of this category there is no measured change to reverse. The clear exception is testosterone-related suppression of sperm production, which is a documented effect with its own clinical management — an integrated analysis in the Lancet in 2006 reported a median 3.4 months for sperm concentration to recover to 20 million per mL, with about 90 percent of men reaching that threshold within 12 months.
For semaglutide the approved labeling gives at least two months before a planned pregnancy, tied to an elimination half-life of about one week. The approved tirzepatide labeling publishes no pre-pregnancy interval, so that timing is your physician's judgment.
Not in this catalog, and nothing here is prescribed as a fertility treatment. Kisspeptin has a genuine reproductive-endocrinology literature, including use as a trigger for egg maturation in IVF reported in the Journal of Clinical Investigation in 2014, but that work was done inside monitored cycles by specialists.
It is not prescribed for that and should not be treated as a fertility treatment. Kisspeptin acts on the same axis fertility medicine acts on, which is a reason for more caution when conception is the goal rather than less. If you are in an IVF cycle or actively trying, raise kisspeptin with the physician managing that care first.
The approved tirzepatide labeling states that hormonal contraceptives not taken by mouth are not expected to be affected; the guidance about switching methods or adding a barrier is specific to oral ones. Confirm it with your own physician rather than assuming.
The drug interactions section of the approved semaglutide label reports no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel alongside semaglutide. That is a documented difference from tirzepatide, worth raising with your physician.
No peptide in this catalog has human data on semen parameters, so the answer is unknown for all of them. What does have data is body weight: a 2021 meta-analysis in Andrologia reported lower semen volume, total sperm number, forward progression and viability with obesity. And exogenous testosterone suppresses sperm production, which is usually what people are circling when they ask.
Probably not, and treating it as the problem is how people lose months. Twelve months of trying, or six if you are over 35, is the standard threshold for a fertility evaluation, which looks at ovulation, tubes, uterus and a semen analysis. If conception is a near-term goal, a baseline semen analysis removes an unanswerable question later.
Same answer as for you, and it is a physician question. Most of this category has no human fertility data in either sex. If your partner is on testosterone replacement, that is the item with real documented effects on sperm production — see can you take peptides with testosterone. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
— Next step
See what a physician
recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.
Important legal & safety information
The assessment process available on the Pepti website asks a series of medical questions, and the answers provided are reviewed by an independent licensed physician affiliated with our partner physician network. The licensed providers have established exclusionary criteria, and the answers provided determine if the individual is screened out of eligibility for treatment. The licensed clinicians retain the sole decision to prescribe peptide therapy and other compounded medications to patients. Treatment may be denied at the physician's sole discretion. If a prescription is not approved, you will not be charged for the medication.
Pharmacy Providers. Pepti is a technology platform and is not a healthcare provider, pharmacy, or prescriber. All medications offered through the platform are compounded by independent FDA-registered 503A or 503B compounding pharmacies based on a valid prescription written by a licensed physician for an individual patient. Compounded medications are not FDA-approved as products. The active pharmaceutical ingredients used by our partner pharmacies are sourced from FDA-registered facilities. Compounded medications may not undergo the same testing or quality control as commercially manufactured FDA-approved drugs.
Results vary. Results from peptide therapy and other compounded treatments vary based on individual factors, including age, weight, medical history, adherence to the prescribed protocol, lifestyle factors, and physiological response. Pepti makes no guarantee of any specific outcome. Statements about peptide therapy and compounded medications offered through the platform have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Product images. Product photographs and renderings shown on this website are for illustrative purposes only. The appearance of vials, packaging, labeling, and other materials you receive may vary and is determined by the dispensing compounding pharmacy.
Off-label use.Many peptides offered through the platform are prescribed for off-label use. “Off-label” means the medication is being prescribed for a use, dose, or patient population that is not specifically approved by the FDA. Off-label prescribing is legal and common in U.S. medical practice when supported by clinical experience and judgment.
Mailing & shipping. Pepti currently dispenses prescription medication to patients in all 50 states and Washington, D.C.. All orders ship in unbranded, tamper-evident packaging via expedited delivery from our partner compounding pharmacies. Temperature-sensitive medications ship with insulated packaging and ice packs. Shipping is included at no additional cost. We do not currently ship medication outside all 50 states and Washington, D.C., internationally, or to APO/FPO addresses.
Not for emergencies. Pepti is not designed for medical emergencies. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room immediately. For urgent but non-emergency medical questions, contact your primary care provider or use an urgent care service.
No doctor-patient relationship with Pepti. Your use of the platform does not create a doctor-patient relationship between you and pepti LLC. A doctor-patient relationship is established only between you and the independent licensed physician who reviews your intake and prescribes your treatment. The physicians who use the platform are independent contractors and are solely responsible for the medical care they provide.
Prescription medications. All prescription products require a valid prescription from a licensed healthcare provider. By using the platform, you acknowledge that you are at least 18 years old and that the information you provide is true, accurate, current, and complete. Providing false information may result in inappropriate treatment recommendations or denial of service.
Cosmetic & wellness products.Certain products offered through Pepti — including skincare, hair care, body care, supplements, men's grooming, sports recovery, and sexual wellness products — are cosmetic or dietary supplement products, not prescription medications. These products do not require a prescription and are not reviewed or prescribed by a physician. Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Results vary by individual. Consult your healthcare provider before starting any new supplement or topical product, especially if you are pregnant, nursing, or taking other medications.
pepti LLC · Delaware Limited Liability Company · 131 Continental Dr, Suite 305, Newark, DE 19713 · For media or partnership inquiries, email hello@hellopepti.com. For patient support, email support@hellopepti.com. For privacy and HIPAA inquiries, email privacy@hellopepti.com.